NASDAQ:FNCH
Finch Therapeutics Group, Inc. Stock News
$2.30
-0.190 (-7.63%)
At Close: May 03, 2024
Finch Therapeutics Announces Takeda to Accelerate Leadership Role in FIN-524 Ulcerative Colitis Development Program
07:00am, Tuesday, 10'th Aug 2021
SOMERVILLE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveragin
Finch Therapeutics Added to Russell 2000 and Russell 3000 Indexes
07:00am, Monday, 28'th Jun 2021
SOMERVILLE, Mass., June 28, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveragin
Finch Therapeutics: Gut Instinct Says Buy
11:09am, Monday, 14'th Jun 2021
The microbiome is an exciting area of medical research that could help treat numerous medical problems such as Crohn's disease, Parkinson's and more. Finch Therapeutics is developing a treatment for C
Finch Therapeutics to Present at Upcoming Virtual Investor Conferences
07:00am, Friday, 28'th May 2021
SOMERVILLE, Mass., May 28, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging
Finch Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Updates
07:00am, Thursday, 13'th May 2021
SOMERVILLE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or the “Company”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its H
US IPO Weekly Recap: The IPO Market Heats Up In An 11 IPO Week
11:43am, Sunday, 21'st Mar 2021
The IPO market stayed busy this past week, with 11 IPOs raising $3.0 billion. New filers continued to fill the IPO pipeline, with 8 IPOs and 46 SPACs submitting initial filings.
Finch Therapeutics Announces Pricing of Upsized Initial Public Offering
10:32pm, Thursday, 18'th Mar 2021
SOMERVILLE, Mass., March 18, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveragi
